Navigation Links
GENova appoints Dr. Wang Chong to Scientific Advisory Board
Date:9/14/2009

NEW YORK, NY, Sept. 14 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotheropeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, today announced it has appointed Dr. Wang Chong to its Scientific Advisory Board.

Dr. Wang Chong will contribute his considerable expertise to the company as it pursues its mandate to develop, patent and commercialize ground-breaking cancer-fighting biotechnologies, with a focus on breast and prostate cancer.

Aaron Whiteman, CEO of GENova stated, "GENova is proud to have attracted such an esteemed me member of the healthcare industry to assist us in our growth plans."

About Dr. Wang Chong

Dr. Wang Chong is a physician with over 19 years of experience in the healthcare industry, whose expertise lies in raising capital for and listing small to medium-sized companies. Previous positions include CFO and Commercial Director of Phytopharm plc, CEO of Osmetech plc, Life Sciences Analyst at Canaccord Capital (Europe) Ltd, Leader of UK Healthcare Initiatives at premier management consultants Arthur D. Little Inc, and commercial roles at Glaxo Wellcome plc and SmithKline Beecham plc. Chong graduated with a medical degree from King's College London and a MBA from London Business School. He is also a Council Member of the Royal Society of Medicine's Pharmaceutical Medicine Research Section and an Associate of the Securities and Investment Institute.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova appoints Dr. Philip Gould to Scientific Advisory Board
2. GENova issues clarifying press release
3. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
4. GENova files patent for new breast cancer treatment
5. GENova appoints Director of Asian business development
6. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
7. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
8. Genova files patent for new prostate cancer treatment
9. GENova names Dr. John Savin as Vice President
10. GENova names Aaron Whiteman as CEO
11. InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 2016 , ... Diagnotes, a leader in digital healthcare communications, ... system in South Carolina, to provide its secure mobile communication platform. , “Healthcare ... drives workflow efficiencies and improves provider and patient satisfaction,” said Dr. Todd Rowland, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer from cerebral ... United States and account for one death every four minutes. Many people who ... HCR ManorCare is launching a video series called “Your Brain,” in conjunction with its ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... industry, announced today that Legacy Health is expanding its use of Intrigma’s cloud-based ... a highly successful initial proof of concept. The Portland, Oregon based health system ...
(Date:5/3/2016)... ... 03, 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick Pospisil, ... be used to diagnose and treat joint problems. During this procedure, Dr. Pospisil makes ... special lighting system and lens that illuminate and magnify the various structures in the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Finding the right way to address a patient’s condition before it ... now getting on board. , “You do the right thing, at the right time, at ... down, not up,” said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even if ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... to further expand product development, strengthen its disease modeling capabilities and increase market presence. Photo - ... ... ... ... Sino-German High-Tech Fund (SGHF) is an ...
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
Breaking Medicine Technology: